Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab in Moderate to Severe Crohn's Disease
NCT01635621Phase 2Withdrawn
- Sponsor
- UCB
- Start
- Jun 2012
- Primary completion
- Aug 2013
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of olokizumab in Crohn's disease (4 arms), sponsored by UCB. Primary endpoint: Percentage of subjects with clinical response or remission as measured by the Crohn's Disease Activity Index (CDAI) at 8 weeks. Planned start Jun 2012; status: withdrawn.
02
Drugs
olokizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01635621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01635621.